

# CLINICAL DEVELOPMENT SOLUTIONS TO **IMPROVE** **CHRONIC URTICARIA** **RESEARCH**

Despite the availability of a variety of therapeutic options for chronic urticaria (CU), people living with this condition may not tolerate them well while others may require more effective alternatives. Now you can leverage **comprehensive clinical research technology solutions** within our SmartSignals™ platform as well as our **in-house clinical science expertise** to help you deliver new therapies and treatment options.

## **CAPTURE BETTER ePRO DATA**

SmartSignals eCOA enables electronic administration of chronic urticaria symptom diaries, UCT, and other CU assessments to help researchers generate better-quality ePRO data while simplifying the assessment experience for participants. Our clinical and eCOA scientists support your study by advising on diary design, assessment selection and implementation, and best practices.

## **CONDUCT STUDY ACTIVITIES REMOTELY**

Reach the participants you need to meet enrollment goals by offering solutions that facilitate remote study activities. From RTSM to eConsent, eCOA, and Telemedicine, Signant's comprehensive range of solutions and global project teams will help you conduct trial activities anywhere and any way.

## **LAUNCH STUDIES FASTER**

Accelerate the study startup process by obtaining informed consent, enrolling, and randomizing patients faster using our SmartSignals RTSM and eConsent solutions. Both include options that allow for rapid deployment and simplified implementation of protocol amendments. Plus, these solutions facilitate decentralized study designs.

## **OPTIMIZE ENDPOINT RELIABILITY**

Ensure accurate, reliable primary endpoint data: Our Outcome Analytics solution offers statistical monitoring and data visualizations to help identify quality concerns that could impact endpoint reliability such as errors or fraud. Our clinical and data scientists help your team review the data and recommend mitigation strategies to alleviate data concerns, preventing bad data quality from compromising your study results.

## **DIGITALIZE THE PROCESS**

Each solution and service within our SmartSignals evidence generation platform can be applied to a study independently. However, when combined, they create an intuitive and powerful digital ecosystem for creating and managing complex global studies. Plus, every study is supported by a dedicated team of clinical science and operations experts.

### **SCALES USED:**

- CU Symptom Diary
- CU-Q2oL
- CUPP
- UCT
- Hives Severity Score

At Signant, our focus is helping you develop and deliver treatments or therapies faster in order to improve the quality of life for people living with chronic urticaria.

# SIGNANT'S CHRONIC URTICARIA CLINICAL TRIAL EXPERIENCE

Phases



69

Languages

590+

Sites



58

Countries



2,700  
Patients



9

Protocols


## SMARTSIGNALS SOLUTIONS

The SmartSignals solutions can be used individually or integrated together for a seamless, end-to-end digital experience.

eCOA



RTSM



Outcome Analytics



eConsent




Telemedicine



## DISCUSS YOUR NEXT STUDY WITH US

Our global team of therapeutic area experts advise on all areas of the clinical development process, including:

- Clinical science and medicine
- Data analysis
- Regulatory
- Operations and trial administration
- Global logistics



MEET THE EXPERTS